Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07683026 · ClinicalTrials.gov registry record · Phase 2
Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Not yet
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT07683026 is a Phase 2 study that has not yet begun recruiting, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 255 participants.
The verdict
NCT07683026, a Phase 2 study, has not yet begun recruiting, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years. Participants will: * Take golimumab or placebo injections monthly for the duration of the study or until they are diagnosed with either stage 2 or stage 3 Type 1 Diabetes * Visit a study clinic every 6 months for Oral Glucose Tolerance Tests (OGTTs) and other tests until the end of the study
Interventions
- DRUG Golimumab
- DRUG Placebo (matching golimumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2026-08-08 |
| Est. Completion | 2032-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07683026
The ClinicalTrials.gov registry entry for NCT07683026 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Golimumab is the first listed.
NCT07683026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07683026 about?
NCT07683026 is a clinical study titled "Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo". The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years. Participants will: * Take golimumab or placebo injections monthly f...
What is the current status of trial NCT07683026?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2026-08-08. Estimated completion is 2032-09-01.
What interventions are being tested in trial NCT07683026?
The interventions under investigation include: Golimumab (DRUG), Placebo (matching golimumab) (DRUG).
Who is sponsoring clinical trial NCT07683026?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.